Business
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the following October investor and industry conferences. Details are below: Cell & Gene Meeting on the Mesa Date: Monday, October 6Time: 8
About this update from Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the following October investor and industry conferences. Details are below: Cell & Gene Meeting on the Mesa Date: Monday, October 6 Time: 8:00 AM MT – 9:00 AM MT Format: Panel Discussion Title: Future Horizons: Emerging Trends and Opportunities in Cell and Gene Therapy Development Date: Monday, October 6 Time: 12:00 PM MT – 12:15 PM MT Format: Company Presentation Chardan Annual Genetic Medicines Conference Date: Tuesday, October 21 Time: 12:00 PM ET – 12:40 PM ET Format: Panel Discussion Title: In Vivo Gene Therapies for Genetic Cardiac Diseases The live webcast of the In Vivo Gene Therapies for Genetic Cardiac Diseases Panel Discussion may be accessed from the Investors section of Tenaya’s website . An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference. About Tenaya Therapeutics Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3 -associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com . Tenaya Contacts Michelle Corral VP, Corporate Communications and Investor Relations [email protected] Investors Anne-Marie Fields Precision AQ [email protected]
View stock analysis, news, and events for Tenaya Therapeutics, Inc.